PROCEDURE
Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles
Status
Completed
Phase
Phase 2 / Phase 3
Enrollment
100
Locations
2
Results
Not posted
Publications
5
Study summary
What the protocol is testing.
The iatrogenic induction of local endometrial injury caused through hysteroscopy or pipelle sampling in the preceding non- transfer cycle improves the IVF outcome parameters in patients with previous IVF failures.
Full detailed description
Endometrial injury was preformed either through hysteroscope during office hysteroscopy through the non touch technique or through pipelle biopsy in the early follicular phase (days 5 to 9) in the preceding cycle of the IVF treatment.
Interventions
Treatment arms and agents.
PROCEDURE
Proceed to COH directly
Timeline
From registration to results.
First posted
Feb 26, 2013
Study start
Mar 2013
Primary completion
May 2016
Study completion
Jun 2016
Results posted
Not reported
Registry updated
Jun 10, 2016
Outcomes
What the study measures.
Primary outcomes
positive bHCG rate
Time frame · through study completion, an average of 2 years
Secondary outcomes
clinical pregnancy rate
Time frame · 2 years
live birth rate
Time frame · 2 years
Ectopic pregnancy rate
Time frame · 2 years
Miscarriage rate
Time frame · 2 years
Ongoing pregnancy rate
Time frame · 2 years
Pregnancy complications (preterm birth, placental abnormalities, bleeding throughout pregnancy, pregnancy related hypertensive disorders, IUGR and SGA)
Time frame · 2 years
Eligibility
Who can take part.
- Minimum age
- 25 Years
- Maximum age
- 42 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: * Personal history of 2 or more failed IVF/ICSI cycles (RIF) * Age\</= 42 years * Good response with good quality embryos in previous attempts (\>2) Exclusion Criteria: * Personal history of endometrial tuberculosis/ antituberculous treatment * Sonographically detected hydrosalpinges * Intramural fibroids distorting the endometrial cavity, submucous myomas or Asherman's syndrome * Thrombophilia
Study locations
2 registered sites.
Greece. Showing up to 24 locations stored in the fast local snapshot.
Assisted Reproduction Unit 3rd Department of Obstetrics & Gynecology, Attikon University Hospital
Athens, Attica, Greece
Assisted Reproduction Unit
Alexandroupoli, Thrace, Greece
Publications
Results and literature.
Related trials
More studies on Ganirelix.
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women
University of Delaware · Estrogen · Premenopause
Phase 4
Recruiting
30
2026-07
Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?
ART Fertility Clinics LLC · Healthy
Not applicable
Not yet recruiting
20
2026-05
INTEnsity of ovariaN Stimulation and Embryo Quality
Fundación Santiago Dexeus Font · Infertility
Phase 4
Completed
110
2026-04
Efficacy of Micronized Natural Progesterone vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.
Instituto Bernabeu · IVF
Phase 4
Completed
150
2026-03
IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols
Hanoi Medical University · Infertility (IVF Patients) · Embryo Morphokinetics
Not applicable
Recruiting
148
2026-02
PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study
University Hospital, Ghent · Ovarian Stimulation · Quality of Life
Phase 4
Recruiting
60
2025-12
DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT
Tam Anh TP. Ho Chi Minh General Hospital · Diminished Ovarian Reserve
Not applicable
Recruiting
730
2025-12
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.